Enlituo Cetuximab Beta Injection

1. Indications and Usage
Metastatic Colorectal Cancer (mCRC): Treatment of EGFR-expressing, RAS wild-type metastatic colorectal cancer as monotherapy or in combination with chemotherapy.
Head and Neck Cancer: Treatment of recurrent or metastatic head and neck squamous cell carcinoma, typically in combination with radiotherapy.
Genetic Requirement: Use is strictly restricted to patients confirmed to be RAS wild-type via validated diagnostic testing.
2. Dosage and Administration
Route of Administration: Intravenous infusion ONLY.
Standard Dosage: Initial dose of 400 mg/m² over 120 minutes; subsequent weekly doses of 250 mg/m² over 60 minutes.
Critical Administration Instructions:
Pre-medication: Premedication with an H1 receptor antagonist and corticosteroids is mandatory prior to the first infusion to mitigate hypersensitivity risks.
Dilution: Must be diluted in 500 mL of 0.9% Sodium Chloride Injection.
Infusion Rate: Maximum infusion rate must not exceed 10 mg/min.
3. Mechanism of Action
EGFR Binding: Cetuximab is a chimeric monoclonal antibody that binds with high affinity to the extracellular domain of EGFR.
Signal Inhibition: It competitively inhibits ligand binding, blocking downstream signaling pathways responsible for cell proliferation and survival.
Antitumor Effect: This blockade suppresses tumor growth and promotes tumor cell apoptosis.
4. Safety and Warnings
Hypersensitivity: Severe, potentially fatal hypersensitivity reactions (including anaphylaxis) can occur, often associated with anti-α-gal antibodies.
Cardiopulmonary Mortality: Fatal cardiopulmonary arrests have been reported during or shortly after infusion.
Dermatologic Toxicity: Acneiform rash is a common and clinically significant side effect.
Embryo-Fetal Toxicity: May cause fetal harm; effective contraception is required during treatment.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Acneiform rash, asthenia, fatigue, nausea, vomiting, diarrhea, abdominal pain, and infusion reactions.
Serious Adverse Reactions: Severe cutaneous reactions, infusion-related hypersensitivity, and cardiopulmonary arrest.
Clinical Research Highlights: Clinical trials have demonstrated significant survival benefits in RAS wild-type mCRC when combined with chemotherapy.
6. Drug Interactions
Radiotherapy: Concomitant use with radiotherapy may increase the risk of dermatologic toxicity.
Chemotherapy: When combined with irinotecan-based chemotherapy, the risk of severe diarrhea and neutropenia may be increased.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Cetuximab (recombinant DNA-derived).
Appearance: Clear to slightly opalescent, colorless to pale yellow liquid.
Packaging: Available in various vial sizes (e.g., 100 mg/20 mL).
Storage: Store at 2°C to 8°C. Do not freeze or shake.